The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of investors who purchased CytomX Therapeutics, Inc. (NASDAQ: CTMX) securities between May 17, 2018 and May 13, 2020.
According to the CytomX lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) CytomX had downplayed issues with CX-072’s efficacy observed in the PROCLAIM-CX-072 clinical program; (ii) CytomX had similarly downplayed issues with CX-2009’s efficacy and safety observed in the PROCLAIM-CX-2009 clinical program; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in CytomX you have until July 20, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
To receive more information, please fill out the form.